Toward molecular imaging-driven drug development in oncology

With current testing strategies, the number of novel targeted anticancer agents will exceed our drug selection capacity. Molecular imaging is a powerful additional tool that can assist us in selecting effective drugs and help patients benefit from targeted agents. Moreover, measurement of the functi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer discovery 2011-06, Vol.1 (1), p.25-28
Main Authors: de Vries, Elisabeth G E, Oude Munnink, Thijs H, van Vugt, Marcel A T M, Nagengast, Wouter B
Format: Article
Language:English
Subjects:
Animals
Clinical Trials as Topic
Drug Approval - economics
Drug Approval - methods
Drug Discovery - economics
Drug Discovery - methods
Drug Evaluation, Preclinical
Humans
Molecular Imaging - methods
Molecular Targeted Therapy - economics
Molecular Targeted Therapy - methods
Neoplasms - drug therapy
Neoplasms - economics
Precision Medicine - economics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With current testing strategies, the number of novel targeted anticancer agents will exceed our drug selection capacity. Molecular imaging is a powerful additional tool that can assist us in selecting effective drugs and help patients benefit from targeted agents. Moreover, measurement of the functional effects of such targeted agents could permit dynamic tuning of treatment selection at the earliest time point at which loss of functional effects is observed.
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8274.CD-11-0051